RxDoctor Payments Data
★ My doctorsLook up a doctor →

Wilnelia Medina-Torres

Endocrinology, Diabetes & Metabolism · Manati, PRNPI 1942793047

Payments from drug & device makers

$5,502in general payments, 2019–2025

Across 163 payments — averaging $33.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • Amgen$477
  • Boehringer Ingelheim$475
  • Dexcom, Inc.$369
  • Novo Nordisk$354
  • Sanofi-aventis U.S. LLC$341
  • plus $2K from 17 others

What the payments were for

  • Travel & lodging$96918%
  • Food & beverage$4,51182%
  • Education$220%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic21$1,222
Amgen12$477
Boehringer Ingelheim11$475
Dexcom, Inc.14$369
Novo Nordisk18$354
Sanofi-aventis U.S. LLC11$341
AstraZeneca12$291
Eli Lilly Export S.A. Puerto Rico Branch12$277
Lilly USA, LLC3$239
Bayer2$185
PBG Puerto Rico LLC9$178
AbbVie8$170
Abbott6$129
Novartis6$128
Kyowa Kirin, Inc.1$126
Corcept Therapeutics2$125
Madrigal Pharmaceuticals1$118
Bayer Puerto Rico Inc.6$112
Rhythm Pharmaceuticals, Inc.2$50
Johnson & Johnson2$47
Merck2$38
Boston Scientific1$29
Acella Pharmaceuticals, LLC1$22

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,502 in reported general payments places this provider in the 50th percentile of 143 endocrinology, diabetes & metabolism providers in Puerto Rico.

See all endocrinology, diabetes & metabolism providers in Puerto Rico →

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide11$10,827
Synjardy XrEmpagliflozin/Metformin Hcl12$8,643
SynthroidLevothyroxine Sodium64$3,658
LantusInsulin Glargine,hum.Rec.Anlog12$985
Rosuvastatin Calcium53$386
Hydrocortisone15$345
Atorvastatin Calcium37$287
Pioglitazone Hcl28$281
Gabapentin20$227
Losartan Potassium18$126
Metoprolol Succinate11$120
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide21$110
Lisinopril32$92
Amlodipine Besylate15$45
Metformin Hcl12$45

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$354$10,82711 claims
Boehringer IngelheimSynjardy Xr$475$8,64312 claims
AbbVieSynthroid$170$3,65864 claims
Sanofi-aventis U.S. LLCLantus$341$98512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 143 endocrinology, diabetes & metabolism providers in Puerto Rico.

Other endocrinology, diabetes & metabolism in Manati

See the full list for Puerto Rico →

Where these figures come from

Is this you, or does something look wrong? →